Citron Research Out Negative on J2 Global (JCOM)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Early Valeant/Walgreens Boots Prescription Trends Continuing to Look Positive - Guggenheim (VRX) (WBA)
March 11, 2016 9:37 AM ESTGuggenheim affirms Valeant Pharma (NYSE: VRX) with a Buy rating and $145 price target following recent dermatology prescription performance checks.
Analyst Louise Chen noted the following on Friday:
VRX dermatology Rxs reached ~80% of their levels prior to any disruption from Philidor (October '15) levels up from ~75% last week. TRx's for derm... MoreJ2 Global (JCOM) Comments on Citron Report; Calls 'Factually Incorrect'
March 11, 2016 6:06 AM ESTj2 Global, Inc. (Nasdaq: JCOM). j2 is aware of a report issued yesterday that we believe is both factually incorrect and wrongly... More
UPDATE: Is J2 Global (JCOM) Short a Blast from the Past?
March 10, 2016 2:06 PM EST(Updated - March 10, 2016 3:04 PM EST)
Some traders are suggesting Citron Research was recommending a short on J2 Global (NASDAQ: JCOM) 10 years ago when it was Stocklemon. It is unclear if this is the case. Shares are hitting the lows of the session down 20%... More
